Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,821B 74.8B 66.76B 61.43B 55.76B 106B 7,011B 108B 735B 293B 3,753B 281B 275B P/E 2026 *
23.2x
P/E 2027 * 20.5x
Enterprise Value 10,904B 68.99B 61.58B 56.66B 51.43B 97.46B 6,467B 99.88B 678B 270B 3,462B 259B 253B EV / Sales 2026 *
7.83x
EV / Sales 2027 * 7x
Free-Float
38.12%
Yield 2026 *
1.88%
Yield 2027 * 2.12%
1 day+6.16%
1 week+5.77%
Current month+5.77%
1 month+19.57%
3 months+5.77%
6 months-9.87%
Current year-12.79%
1 week 21
Extreme 21
23.35
1 month 18.33
Extreme 18.33
23.35
Current year 18.33
Extreme 18.33
34.84
1 year 18.33
Extreme 18.33
34.84
3 years 14.52
Extreme 14.52
34.84
5 years 10.99
Extreme 10.99
34.84
10 years 4.49
Extreme 4.4875
100
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+6.16%+5.77% - - 74.8B
+4.28%+0.07%+52.75%+138.78% 1,258B
+2.13%+4.27%+51.21%+91.36% 679B
+0.68%+1.54%+33.83%+112.47% 518B
+2.77%+0.98%+49.44%+68.46% 390B
+1.38%+0.27%+72.42%+45.30% 367B
+0.29%+1.48%+30.84%+58.32% 307B
+0.98%+1.49%+9.04%+34.78% 293B
+1.04%-0.05%+45.29%+76.18% 252B
+1.46%-0.59%+42.48%+125.82% 210B
Average +2.15%+1.05%+43.03%+83.50% 475B
Weighted average by Cap. +2.38%+1.18%+46.08%+96.39%

Financials

2026 *2027 *
Net sales 1,393B 8.81B 7.87B 7.24B 6.57B 12.45B 826B 12.76B 86.58B 34.51B 442B 33.07B 32.37B 1,522B 9.63B 8.6B 7.91B 7.18B 13.6B 903B 13.94B 94.61B 37.71B 483B 36.14B 35.37B
Net income 510B 3.22B 2.88B 2.65B 2.4B 4.55B 302B 4.67B 31.68B 12.63B 162B 12.1B 11.84B 577B 3.65B 3.26B 3B 2.72B 5.16B 342B 5.28B 35.86B 14.29B 183B 13.7B 13.41B
Net Debt -918B -5.81B -5.18B -4.77B -4.33B -8.2B -544B -8.41B -57.05B -22.74B -291B -21.79B -21.33B -1,165B -7.37B -6.58B -6.05B -5.49B -10.41B -691B -10.67B -72.41B -28.86B -370B -27.66B -27.07B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
09/11/26 $22.91 +6.16% 191,576
06/11/26 $21.58 -3.01% 210,842
05/11/26 $22.25 +0.59% 902,434
04/11/26 $22.12 +2.79% 148,308
03/11/26 $21.52 -0.65% 114,545
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,185.00JPY
Average target price
8,393.33JPY
Spread / Average Target
+16.82%